c19early.org COVID-19 treatment researchCOVID-19 treatments

Supplementary Data — Cetylpyridinium Chloride reduces COVID-19 risk: real-time meta-analysis of 4 studies

@CovidAnalysis, November 2026, Version 6V6 (V1 2023)

.fp--anim .fp__study,.fp--anim .fp__sum,.fp--anim .fp__het,.fp--anim .fp__dia,.fp--anim .fp__verdict,.fp--anim .fp__pooled{opacity:1}.fp--anim .fp__ci{transform:none}.fp--anim .fp__pt{transform:translate(-50%,-50%)}.fp--anim .fp__plot::before{opacity:var(--shade-opacity)}.fp--anim-settle .fp__pt{left:calc(min(var(--pt),var(--max))/var(--max)*100%)}.fp--anim-settle .fp__ci,.fp--anim-settle .fp__dia{left:calc(var(--lo)/var(--max)*100%);width:calc((var(--hi) - var(--lo))/var(--max)*100%)}

Cetylpyridinium chloride COVID-19 outcomes

November 2026

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk

Bonn (DB RCT)85%0.15 · 0.01–2.74viral load6 (n)9 (n)Short term viral CT¹ Gansky (DB RCT)60%0.40 · 0.02–7.68no recov.0/31/6AMPoL Ponphaib.. (DB RCT)36%0.64 · 0.46–0.89no recov.25/5342/57CT¹ Ponphaib.. (DB RCT)24%0.76 · 0.64–0.89no recov.43/5955/57CT¹ Ponphaib.. (DB RCT)14%0.86 · 0.77–0.97no recov.50/5956/57CT¹ Ponphaib.. (DB RCT)30%0.70 · 0.59–0.84no recov.40/5955/57CT¹ Rengifo (DB RCT)68%0.32 · 0.01–7.20hosp.0/121/11CT¹ Rengifo (DB RCT)83%0.17 · 0.02–1.20viral+1/125/10CT¹

00.511.52+

¹ CT: study uses combined treatment

Rotate screen for more detailsIncrease width for more details

← CPC
reduces riskCPC
increases risk →

Fig. S1. All outcomes.